Founded and operated by leaders and scientists from the diagnostics industry, CIRCULOGENE is the leader in molecular testing. By applying proprietary cell-free DNA recovery and enrichment technology, CIRCULOGENE is the first and only company to use minimal volumes of blood to monitor tumors and the first company to develop a next-generation sequencing method to provide full genomic load analysis.

Mike Mullen | President and CEO

Mike Mullen has more than 25 years in executive and financial leadership positions. He was most recently the President and CEO of Atherotech Diagnostics. Prior to Atherotech, Mike held various financial positions with several companies including Ernst &Young. Mike holds both medical technology and accounting degrees and was the Southeast recipient of the Ernst & Young Entrepreneur of the Year award in 2014.

Daniel Coleman | Strategic Advisor

Daniel was the CEO of KCG Holdings, a New York-based public company with offices in Europe and Asia. Created in 2013 through the merger of Knight Capital Group and GETCO LLC, KCG was a leading trader of equities, futures, government bonds and options around the world. Prior to KCG, Daniel was CEO of GETCO, a privately held, automated trading firm based in Chicago. Daniel’s past board memberships include NASDAQ and The Boston Options Exchange. Daniel holds a B.A. from Yale University and an M.B.A. from the University of Chicago.

Stephen Eck, M.D., Ph.D.

Dr. Stephen Eck is an experienced Medical Oncologist with a demonstrated history of working in the biotechnology industry as a Chief Executive and Medical Officer. He has extensive experience in the development of genetically targeted pharmaceuticals and diagnostics. Dr. Eck is also a strong business development professional, is Board Chair of the Personalized Medicine Coalition and serves on the Board of Directors of Luminex Corporation (LMNX). He received an B.A. in chemistry from Kalamazoo College, an M.S. and a Ph.D. in chemistry from Harvard University and an M.D. from the University of Mississippi and a Fellowship in Hematology and Oncology at the University of Michigan.

Richard Lanman, MD.

Dr. Lanman was most recently the Global Chief Medical Officer at Guardant Health where he planned and executed research studies, publications, and physician education in oncology genomics required to obtain their broad insurance coverage, incorporation in clinical guidelines and FDA approvals and clearances. Dr. Lanman served similar capacities as the Chief Medical Officer at cytology-based genomics testing company Veracyte as well as at two cardiovascular bio-diagnostics companies, diaDexus and Atherotech. Dr. Lanman graduated Stanford with a B.S. in Chemistry before obtaining his M.D. at Northwestern University School of Medicine and completing his residency at UCSF Moffit Hospital.

James E. Cantrell, Jr., M.D.

Dr. Cantrell has practiced Oncology-Hematology over 30 years and was a Co-founder and President of Alabama Oncology, LLC and Medical Director of the Bruno Cancer Center. He has published over 20 peer reviewed articles and abstracts and has been a member of numerous professional organizations, including the US Oncology Research Program. He earned his M.D. and completed an Internal Medicine Residency at Emory University School of Medicine and completed fellowships in Medical Oncology and Hematology at Georgetown University Hospital.

Robert Garvie | Strategic Advisor

“Bob” has sold or taken public several healthcare companies spanning his 30-plus years as an executive and business operator. Bob sold EndoVia, a Boston-based surgical robotics company, to Hansen Medical, took ArthoCare – a Sunnyvale, California-based surgical company – through IPO, and acquired the Haemonetics surgical products division where he also led R&D and Commercial Operations.  Bob holds both a master’s degree in Physiology/Pharmacology and bachelor’s degree in biology from the University of California San Diego.